1
|
Yao W, Shi L, Zhang Y, Dong H, Zhang Y. Mesenchymal stem/stromal cell therapy for COVID-19 pneumonia: potential mechanisms, current clinical evidence, and future perspectives. Stem Cell Res Ther 2022; 13:124. [PMID: 35321737 PMCID: PMC8942612 DOI: 10.1186/s13287-022-02810-6] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2021] [Accepted: 02/07/2022] [Indexed: 12/20/2022] Open
Abstract
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread into more than 200 countries and infected approximately 203 million people globally. COVID-19 is associated with high mortality and morbidity in some patients, and this disease still does not have effective treatments with reproducibly appreciable outcomes. One of the leading complications associated with COVID-19 is acute respiratory distress syndrome (ARDS); this is an anti-viral host inflammatory response, and it is usually caused by a cytokine storm syndrome which may lead to multi-organ failure and death. Currently, COVID-19 patients are treated with approaches that mostly fall into two major categories: immunomodulators, which promote the body's fight against viruses efficiently, and antivirals, which slow or stop viruses from multiplying. These treatments include a variety of novel therapies that are currently being tested in clinical trials, including serum, IL-6 antibody, and remdesivir; however, the outcomes of these therapies are not consistently appreciable and remain a subject of debate. Mesenchymal stem/stromal cells (MSCs), the multipotent stem cells that have previously been used to treat viral infections and various respiratory diseases such as ARDS exhibit immunomodulatory properties and can ameliorate tissue damage. Given that SARS-CoV-2 targets the immune system and causes tissue damage, it is presumable that MSCs are being explored to treat COVID-19 patients. This review summarizes the potential mechanisms of action of MSC therapy, progress of MSC, and its related products in clinical trials for COVID-19 therapy based on the outcomes of these clinical studies.
Collapse
Affiliation(s)
- Weiqi Yao
- Department of Hematology, Union Hospital, Tong Ji Medical College, Hua Zhong University of Science and Technology, Hubei, China
- State Industrial Base for Stem Cell Engineering Products, No. 12 Meiyuan Road, Tianjin, 300384, China
- Hubei Engineering Research Center for Human Stem Cell Preparation, Application and Resource Preservation, Wuhan, China
| | - Lei Shi
- Department of Infectious Diseases, Fifth Medical Center of Chinese, PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China
| | - Yun Zhang
- State Industrial Base for Stem Cell Engineering Products, No. 12 Meiyuan Road, Tianjin, 300384, China
- Tianjin Key Laboratory for Stem Cell and Regenerative Medicine, Tianjin, China
| | - Haibo Dong
- Hubei Engineering Research Center for Human Stem Cell Preparation, Application and Resource Preservation, Wuhan, China
- Wuhan Optics Valley VCANBIO Cell & Gene Technology Co., Ltd., Hubei, China
| | - Yu Zhang
- State Industrial Base for Stem Cell Engineering Products, No. 12 Meiyuan Road, Tianjin, 300384, China.
- Hubei Engineering Research Center for Human Stem Cell Preparation, Application and Resource Preservation, Wuhan, China.
- Tianjin Key Laboratory for Stem Cell and Regenerative Medicine, Tianjin, China.
- Tianjin Key Laboratory for Blood Cell Therapy Technology, Tianjin, China.
| |
Collapse
|
2
|
Kesari S, Kasper GC, Verkh L, Hammond TC, Matal ML, Hammerling JW, Tankovich N, Lim AP, Zhao KH, Juarez T, Redfern RE, Gill JM, Nomura N, Hiemer A, Heng A, Shoemaker J. Correction to: Mesenchymal stem cells in the treatment of severe COVID-19. TRANSLATIONAL MEDICINE COMMUNICATIONS 2021; 6:19. [PMID: 34458585 PMCID: PMC8381133 DOI: 10.1186/s41231-021-00098-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
[This corrects the article DOI: 10.1186/s41231-021-00095-0.].
Collapse
Affiliation(s)
- Santosh Kesari
- Pacific Neuroscience Institute and Providence Saint John’s Health Center, Santa Monica, USA
| | - Gregory C. Kasper
- ProMedica Toledo Hospital, 2142 North Cove Blvd, Toledo, OH 43606 USA
| | - Lev Verkh
- Stemedica Cell Technologies, Inc., San Diego, USA
| | | | - Marla L. Matal
- ProMedica Toledo Hospital, 2142 North Cove Blvd, Toledo, OH 43606 USA
| | - Jay W. Hammerling
- ProMedica Toledo Hospital, 2142 North Cove Blvd, Toledo, OH 43606 USA
| | | | - Adrianus P. Lim
- ProMedica Toledo Hospital, 2142 North Cove Blvd, Toledo, OH 43606 USA
| | - Kevin H. Zhao
- ProMedica Toledo Hospital, 2142 North Cove Blvd, Toledo, OH 43606 USA
| | - Tiffany Juarez
- Pacific Neuroscience Institute and Providence Saint John’s Health Center, Santa Monica, USA
| | | | - Jaya M. Gill
- Pacific Neuroscience Institute, Santa Monica, USA
| | - Natsuko Nomura
- Pacific Neuroscience Institute and Providence Saint John’s Health Center, Santa Monica, USA
| | - Audrey Hiemer
- Pacific Neuroscience Institute and Providence Saint John’s Health Center, Santa Monica, USA
| | - Annie Heng
- Pacific Neuroscience Institute and Providence Saint John’s Health Center, Santa Monica, USA
| | - Jessica Shoemaker
- ProMedica Toledo Hospital, 2142 North Cove Blvd, Toledo, OH 43606 USA
| |
Collapse
|